Stimuli-responsive block copolymers

Abstract

In various embodiments, the present disclosure relates to compositions for medical applications. In some embodiments, the compositions comprise one or more poly(N-isopropylaminoacrylamide) blocks and one or more poly(2-(di-(C 1~5 )Alkylamino)(C 1~5 In some embodiments, the composition is in liquid form at 25° C. Other embodiments relate to methods comprising delivering such a composition to a patient.

Description

[Technical Field]

[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 282,349, filed November 23, 2021, the entire disclosure of which is incorporated herein by reference for all purposes.

[0002] The present disclosure relates to stimulus-responsive block copolymers, compositions containing such stimulus-responsive block copolymers, and methods of using such stimulus-responsive block copolymers. The stimulus-responsive block copolymers of the present disclosure are useful in a variety of biomedical applications, including, for example, embolization. [Background technology]

[0003] Liquid embolic systems are increasingly being accepted as effective agents for embolization or filling of neurological and peripheral diseases, such as hypervascular tumors, arteriovenous malformations, aneurysms, and endoleaks. DMSO solvent-based technologies used in commercial or developmental products, such as Onyx® (Medtronic), Squidperi™ (Emboflu / Balt), PHIL™ (Terumo), and Easyx™ (Antia AG), are based on the change in solubility of the embolic polymer during its transition from the DMSO solvent to blood water. These technologies have limitations due to the inherent toxicity of DMSO, which can cause tissue necrosis and vasospasm. The presence of DMSO in formulations can also result in patients noticing a strong odor similar to garlic after the procedure, which requires additional administrative procedures, such as informed consent, to ensure each patient is aware of this potential side effect.

[0004] Aqueous systems have a lot of appeal to physicians and patients in this field because they eliminate DMSO. They also have the potential for greater biocompatibility and ease of use. This could also have the potential for drug-loading applications, if desired, as well as for benign embolization in a variety of indications.

[0005] Several notable aqueous-based products have undergone development and preclinical testing. For example, the polyelectrolyte GPX™ system (Fluidx Medical) uses electrostatically condensed, oppositely charged polyelectrolytes, polycationic salmine sulfate (Sal) and polyanion sodium inositol hexaphosphate (IP6), to form a coacervate formed by charge interaction. A specific property of the polyelectrolyte complex is that the charge interaction between the polymer chains can be shielded by a high ionic strength NaCl solution (1200 mM), resulting in a clear, homogeneous, low-viscosity fluid. Subsequent release of NaCl during in vivo delivery results in a sol-gel transition to a high-viscosity coacervate. Tantalum powder is mixed with the formulation to provide the required radiopacity under a fluoroscope. Obsidio hydrogel is a novel bioengineered tantalum-loaded nanocomposite gel embolic material (Ta-GEM). The system was formulated by mixing gelatin (Type A, 18%), silicate nanoplatelets (Laponite XLG, 9%), ultrapure water, and tantalum powder (2 μm, 20%, w / w). The disk-like Laponite nanoplatelets have negative charges on two faces, which can interact with the positively charged gelatin to form a composite gel structure. Other aqueous hydrogels that have been reported are PuraMatrix™, a polypeptide hydrogel, and SELP (Silk-elastin-like Protein Polymer, University of Utah), a temperature-sensitive system. Summary of the Invention

[0006] In various embodiments, the present disclosure relates to compositions for medical applications. The compositions include one or more poly(N-isopropylaminoacrylamide) blocks and one or more poly(2-(di-(C 1~5 ) alkylamino)(C 1~5 ) alkyl methacrylate) block, each C 1~5The alkyl groups are independently selected from methyl, ethyl, propyl, butyl, and pentyl groups. 1~5 Each of the alkyl groups is identical to the others.

[0007] In some embodiments, the composition comprises one or more poly(N-isopropylaminoacrylamide) blocks and one or more poly(2-(di-(C 1~5 ) alkylamino) ethyl methacrylate block, each C 1~5 The alkyl groups are independently selected from methyl, ethyl, propyl, butyl, and pentyl groups. 1~5 Each of the alkyl groups is identical to the others.

[0008] In various embodiments that may be used in conjunction with the above embodiments, one or more poly(2-(di-(C 1~5 ) alkylamino)(C 1~5 ) alkyl methacrylate) block is poly(2-(di-(C 3~5 ) alkylamino) ethyl methacrylate) blocks, more typically poly(2-(dibutylamino) ethyl methacrylate) blocks.

[0009] In various embodiments that can be used in conjunction with the above embodiments, the composition is in liquid form at 25°C. In various embodiments that can be used in conjunction with the above embodiments, the composition has a pH in the range of 1-7.4, typically in the range of 4.5-6.5, and more typically in the range of 5-6.

[0010] In various embodiments that can be used in conjunction with the above embodiments, the composition becomes a gel when injected into phosphate buffered saline having a pH of 7.4 and a temperature of 37°C (e.g., at 20-25°C).

[0011] In various embodiments that can be used in conjunction with the above embodiments, the composition becomes a gel when injected (e.g., at 20-25°C) into the vascular system of a patient (e.g., a mammalian patient such as a human).

[0012] In various embodiments that can be used in conjunction with the above embodiments, the block copolymer comprises two poly(N-isopropylaminoacrylamide) blocks and one poly(2-(di-(C 1~5 ) alkylamino)(C 1~5 ) alkyl methacrylate) blocks, more typically two poly(N-isopropylaminoacrylamide) blocks and one poly(2-(di-(C 3~5 It is a triblock copolymer having a) alkylamino) ethyl methacrylate) block.

[0013] In various embodiments that can be used in conjunction with the above embodiments, the block copolymer comprises one poly(N-isopropylaminoacrylamide) block and two poly(2-(di-(C 1~5 ) alkylamino)(C 1~5 ) alkyl methacrylate) block, more typically one poly(N-isopropylaminoacrylamide) block and two poly(2-(di-(C 3~5 It is a triblock copolymer having a) alkylamino) ethyl methacrylate) block.

[0014] In various embodiments that can be used in conjunction with the above embodiments, each of the one or more poly(N-isopropylaminoacrylamide) blocks in the block copolymer ranges from 5 to 1000 monomer units in length, more typically from 100 to 600 monomer units in length.

[0015] In various embodiments that can be used in conjunction with the above embodiments, one or more poly(2-(di-(C 1~5 ) alkylamino)(C 1~5Each of the )alkyl methacrylate) blocks ranges from 10 to 500 units in length, more typically from 50 to 300 monomer units in length.

[0016] In various embodiments that can be used in conjunction with the above embodiments, the block copolymer has a number average molecular weight in the range of 2000 to 500,000 Da. In various embodiments that can be used in conjunction with the above embodiments, the block copolymer is present in the composition at a concentration ranging from 1 to 50% wt / wt, based on the weight of the composition.

[0017] In various embodiments that can be used in conjunction with the above embodiments, the composition has a viscosity in the range of 10 mPa·s to 5000 mPa·s when measured at a temperature of 25° C. and a shear rate of 50 1 / s.

[0018] In various embodiments that can be used in conjunction with the above embodiments, the block copolymer further comprises an additional polymer block ranging from 1 to 500 monomer units in length that comprises an amine group. For example, the amine group can be selected from, among others, aminoalkyl groups, alkylaminoalkyl groups, and dialkylaminoalkyl groups.

[0019] In various embodiments that can be used in conjunction with the above embodiments, the composition, in addition to the block copolymer, further comprises an anionic polymer that includes negatively charged groups selected from sulfonate groups, sulfate groups, phosphate groups, phosphonate groups, and carboxylate groups, among others.

[0020] In various embodiments that can be used in conjunction with the above embodiments, the anionic polymer has a number average molecular weight in the range of 1000 to 5,000,000 Da. In various embodiments that can be used in conjunction with the above embodiments, the anionic polymer is present in an amount ranging from 0.1 to 50% wt / wt by weight of the composition.

[0021] In various embodiments that can be used in conjunction with the above embodiments, the anionic polymer is selected from sulfonate polymers, polyphosphates, poly(carboxylic acids), and negatively charged polysaccharides, among others.

[0022] In various embodiments that can be used in conjunction with the above embodiments, the composition further comprises an imaging agent. For example, the imaging agent can be a radiological contrast agent, which in some cases can include, for example, metal particles.

[0023] In various embodiments that can be used in conjunction with the above embodiments, the composition further comprises an inorganic salt, such as sodium chloride or potassium chloride, among others, which may be present at a concentration ranging from 0.2 M to 5.0 M, more typically from 0.5 M to 2.0 M, among other possible values.

[0024] In various embodiments that can be used in conjunction with the above embodiments, the composition further comprises a therapeutic agent. In various embodiments that can be used in conjunction with the above embodiments, the composition is provided in a vial or syringe barrel.

[0025] In various embodiments, the present disclosure relates to a method comprising delivering to a patient a composition according to any of the above embodiments. In some embodiments, the method is a therapeutic method and the composition is delivered into the vasculature of a patient. For example, the therapeutic method can be selected from, among others, a method for treating a tumor, a method for treating an arteriovenous malformation, a method for treating an aneurysm, a method for treating an endoleak, a method for treating gastrointestinal bleeding, or a method for treating bleeding caused by disease or trauma.

[0026] In some embodiments, the method includes delivering the composition to the patient as a fiducial marker. In some embodiments, the method includes delivering a composition between a first tissue and a second tissue of the patient, thereby spacing the first tissue from the second tissue.

[0027] In various embodiments, the present disclosure relates to the use of the composition of any of the above embodiments as, inter alia, an embolic agent, a fiducial marker, a tissue filler, a tissue spacer, or a therapeutic agent depot. [Brief explanation of the drawings]

[0028] [Figure 1] Schematic diagram of poly(N-isopropylaminoacrylamide)-poly(2-(dibutylamino)ethyl methacrylate)-poly(N-isopropylaminoacrylamide) triblock copolymer, also referred to herein as NIPAAM-DBA-NIPAAM triblock copolymer, pNIPAAM-pDBA-pNIPAAM triblock copolymer, or pNIPAAM-b-pDBA-b-pNIPAAM triblock copolymer. [Figure 2] FIG. 1 is a schematic diagram of a NIPAAM-DBA-NIPAAM triblock copolymer with additional amino groups, according to one embodiment of the present disclosure. [Figure 3] Schematic representation of (a) the phase change during mixing of protonated triblock copolymer with poly(2-acrylamido-2-methylpropanesulfonate) (polyAMPS) to form a coacervate ( FIG. 3A ), (b) the temperature increase that induces NIPAAM aggregation ( FIG. 3B ), and (c) the in vivo pH change that causes partial deprotonation of DBA and enhanced gel hydrophobicity ( FIG. 3C ), according to one embodiment of the present disclosure. [Figure 4] Schematic representation of the synthesis of pNIPAAM-b-pDBA-b-pNIPAAM triblock copolymer, according to one embodiment of the present disclosure. [Figure 5A] FIG. 1 shows proton NMR of a polymer after formation of the initial pNIPAAM block, according to one embodiment of the present disclosure. [Figure 5B] FIG. 1 shows proton NMR of the polymer after formation of the pNIPAAM-b-pDBA diblock copolymer, according to one embodiment of the present disclosure. [Figure 5C]FIG. 1 shows proton NMR of the polymer after formation of the pNIPAAM-b-pDBA-b-pNIPAAMa triblock copolymer, according to one embodiment of the present disclosure. [Figure 5D] FIG. 1 shows proton NMR of pNIPAAM-b-pDBA-b-pNIPAAMa triblock copolymer after purification by dialysis against methanol (dialysis membrane MWCO 12000-14000 Da) according to one embodiment of the present disclosure. [Figure 6] An image of hydrogel formation after delivery into PBS (phosphate buffered saline) at 37° C., according to one embodiment of the present disclosure. [Figure 7] 1 shows the storage and loss modulus versus temperature plots for several charge ratios between the pDBA block of the pNIPAAM-b-pDBA-b-pNIPAAMa triblock copolymer and polyAMPS for the rheological properties of the polymer composites according to embodiments of the present disclosure. The solid symbols are the storage modulus (G') and the open symbols are the loss modulus (G''). [Figure 8] 1 shows a plot of the storage and loss moduli of various pNIPAAM-b-pDBA-b-pNIPAAMa triblock copolymer samples versus a temperature gradient, in accordance with embodiments of the present disclosure. Solid symbols are the storage modulus (G') and open symbols are the loss modulus (G''). [Figure 9] FIG. 10 shows the modulus change induced by adding PBS and by increasing pH, according to one embodiment of the present disclosure. [Figure 10] 1 shows the change in elastic modulus of NIPAAM-DEA-NIPAAM / polyAMPS composite gels (filled symbols) and NIPAAM-DBA-NIPAAM / polyAMPS composite gels (open symbols) according to embodiments of the present disclosure. Square symbols indicate the storage modulus (G'), and triangle symbols indicate the loss modulus (G''). [Figure 11]FIG. 1 shows catheter delivery of a NIPAAM-DBA-NIPAAM / polyAMPS complex into a flow model (PBS medium, 37° C.) according to one embodiment of the present disclosure, in which a foam pad is held in place within a polymer tube by a spring that maintains the foam against the flow of PBS. [Figure 12] 12A-12C show embolization studies of NIPAAM-DBA-NIPAAM / polyAMPS complexes injected into a porcine kidney model. FIG. 12A corresponds to before embolization. FIG. 12B corresponds to after embolization. FIG. 12C corresponds to contrast injection after embolization. [Figure 13] 13A-13C show embolization studies of a reference composition injected into a pig kidney model, according to one embodiment of the present disclosure. Fig. 13A corresponds to before embolization, Fig. 13B corresponds to after embolization, and Fig. 13C corresponds to contrast injection after embolization. DETAILED DESCRIPTION OF THE INVENTION

[0029] In various embodiments, the present disclosure provides a polymerizable composition comprising one or more poly(N-isopropylaminoacrylamide) blocks and one or more poly(2-(di-(C 1~5 ) alkylamino)(C 1~5 ) alkyl methacrylate) blocks, 1~5 The alkyl groups are independently selected from methyl, ethyl, propyl (where propyl includes n-propyl and isopropyl), butyl (where butyl includes n-butyl, isobutyl, sec-butyl and tert-butyl), and pentyl (where pentyl includes n-pentyl, tert-pentyl, neopentyl, isopentyl, sec-pentyl, 3-pentyl, sec-isopentyl, activated pentyl) groups. In various embodiments, the one or more poly(2-(di-(C 1~5 ) alkylamino)(C 1~5 ) alkyl methacrylate) block is poly(2-(di-(C 1~5) alkylamino) ethyl methacrylate) blocks, more typically poly(2-(dibutylamino) ethyl methacrylate) blocks.

[0030] Such compositions include liquid compositions suitable for injection into the body. The compositions of the present disclosure may be provided in a vial or syringe barrel. In some embodiments, the composition in the vial or syringe barrel may be a liquid composition, e.g., an aqueous liquid composition. In some embodiments, the composition in the vial or syringe barrel may be a dry composition, to which an appropriate fluid (e.g., water for injection, 5% dextrose in water (D5W), saline, a buffer solution (e.g., phosphate-buffered saline), etc.) may be added to form a liquid composition. In some embodiments, the vial or syringe may be stored under refrigerated conditions at a temperature ranging from 2 to 8°C. The compositions of the present disclosure may be provided in a sterile form.

[0031] In various embodiments, the compositions of the present disclosure are liquid compositions that form a gel material (also referred to herein as a hydrogel material or a solidified material) in situ upon injection into the body. Such liquid compositions include liquid compositions that can form a gel in response to in vivo conditions. In various embodiments, the liquid composition forms a gel in response to both a change in pH and a change in temperature.

[0032] In various embodiments, the compositions of the present disclosure are in liquid form at room temperature (e.g., below 25°C, or in some embodiments below 30°C) and may have a pH below 7.0, typically in the range of 4.5 to 6.5, more typically in the range of 5 to 6. After delivery to a patient's body (e.g., to in vivo conditions where the temperature is about 37°C and the pH is about 7), the liquid composition spontaneously forms a gel.

[0033] Such liquid compositions can be used in a number of medical applications, including as liquid embolic compositions, fiducial markers, tissue fillers, tissue spacers, and depots containing therapeutic agents from which the therapeutic agents elute into the surrounding tissue.

[0034] In embodiments in which the liquid composition of the present disclosure is injected into a subject's body, the liquid composition can be adapted to pass through the particular delivery device used for injection, preferably with manual pressure. For example, a typical injection involves pressing the plunger with the thumb and stabilizing the sides of the syringe barrel with the index and middle fingers of the same side, with an injection force of less than 50 N being preferred. The desired viscosity level will typically depend on the procedure and delivery method. For direct injection using a needle and syringe, the amount of pressure required will depend, for example, on the gauge of the needle. Similarly, for injection through a catheter, the amount of pressure required will depend, for example, on the inner diameter of the catheter.

[0035] In some embodiments, the liquid compositions of the present disclosure have a viscosity in the range of 10 mPa·s or less to 5000 mPa·s or more when measured at a shear rate of 50 1 / s at a temperature of 25° C. For example, the compositions may have a viscosity anywhere in the range of 10 mPa·s to 25 mPa·s to 50 mPa·s to 100 mPa·s to 250 mPa·s to 500 mPa·s to 1000 mPa·s to 2500 mPa·s to 5000 mPa·s at a shear rate of 50 1 / s and a temperature of 25° C.

[0036] As previously mentioned, the compositions of the present disclosure may comprise one or more poly(N-isopropylaminoacrylamide) blocks and one or more poly(2-(di-(C 1~5 ) alkylamino)(C 1~5 ) alkyl methacrylate) blocks, more typically one or more poly(N-isopropylaminoacrylamide) blocks and one or more poly(2-(di-(C 3~5 )alkylamino)ethyl methacrylate) blocks, for example, block copolymers comprising one or more poly(N-isopropylaminoacrylamide) blocks and one or more poly(2-(dibutylamino)ethyl methacrylate) blocks.

[0037] In some embodiments, each of the poly(N-isopropylaminoacrylamide) blocks is between 5 or less and 1000 or more monomer units in length, e.g., between 5, 10, 25, 50, 100, 300, 600, and 1000 monomer units in length (i.e., between any two of the above values). In certain advantageous embodiments, each of the poly(N-isopropylaminoacrylamide) blocks is greater than 100 monomer units in length and less than 600 monomer units in length.

[0038] In some embodiments, the one or more poly(2-(di-(C 1~5 ) alkylamino)(C 1~5 Each of the poly(2-(di-(C alkyl methacrylate)) blocks has a length ranging from 10 or less to 500 or more monomer units, for example, a length ranging from 10 to 25 to 50 to 75 to 100 to 200 to 250 to 300 to 500 monomer units. In certain advantageous embodiments, the poly(2-(di-(C alkyl methacrylate)) blocks have a length ranging from 10 to 500 monomer units. 1~5 ) alkylamino)(C 1~5 Each of the )alkyl methacrylate) blocks is greater than 50 monomer units in length and less than 300 monomer units in length.

[0039] In some embodiments, the number average molecular weight of the block copolymer ranges from 2,000 Da to 500,000 Da. For example, the number average molecular weight of the block copolymer may be in any range of 2,000 Da to 5,000 Da to 10,000 Da to 20,000 Da to 50,000 Da to 100,000 Da to 200,000 Da to 500,000 Da.

[0040] In some embodiments, the block copolymer is poly(2-(di-(C 1~5 ) alkylamino)(C 1~5 ) alkyl methacrylate) center block and two poly(N-isopropylaminoacrylamide) outer blocks.

[0041] In some embodiments, the block copolymer comprises a poly(N-isopropylaminoacrylamide) center block and two poly(2-(di-(C 1~5 ) alkylamino)(C 1~5 ) alkyl methacrylate) outer blocks. Such triblock copolymers include poly(2-(di-(C 1~5 ) alkylamino)(C 1~5 The poly(2-(dibutylamino)ethyl methacrylate) block is a poly(2-(dibutylamino)ethyl methacrylate) block, as shown in FIG. 1, where l and n are integers. For example, l can be an integer ranging from 10 to 500, and n can be an integer ranging from 5 to 1000.

[0042] In some embodiments, the block copolymer further comprises an additional polymer block comprising an amine group, which can be formed from an amine-containing monomer. For example, the additional polymer block can comprise an amine group selected from an aminoalkyl group (e.g., an amino-C1-C4-alkyl group), an alkylaminoalkyl group (e.g., a C1-C4-alkylamino-C1-C4-alkyl group), or a dialkylaminoalkyl group (e.g., a di-C1-C4-alkyl-amino-(C1-C4-alkyl) group), specific examples of which include aminomethyl, aminoethyl, aminopropyl, methylaminomethyl, dimethylaminomethyl, ethylaminomethyl, diethylaminomethyl, methylaminoethyl, dimethylaminoethyl, ethylaminoethyl, diethylaminoethyl, methylaminopropyl, dimethylaminopropyl, ethylaminopropyl, or diethylaminopropyl groups. In some embodiments, the additional polymer block is in the range of 1 to 500 or more monomer units in length, e.g., in the range of 1 to 500 or more monomer units in length. An example of such a block copolymer is shown in Figure 2, where the amine-containing monomer is 2-aminoethyl methacrylate. Such a monomer may provide, among other purposes, additional functional groups for subsequent linkage with molecules (e.g., thrombin peptides). During synthesis of the block copolymer by the RAFT technique illustrated in Figure 2, the amino group in 2-aminoethyl methacrylate can be protected to avoid interference with chain transfer agents by using common protecting groups. Typical protecting groups include 9-fluorenylmethyl carbamate, t-butyl carbamate, benzyl carbamate, acetamide, and trifluoroacetamide, among others. After polymerization, the protecting groups are deprotected accordingly.

[0043] In some embodiments, the block copolymer is present in a concentration ranging from 1% wt / wt or less to 50% wt / wt or more by weight of the composition, which may be a liquid composition, e.g., an aqueous liquid composition. For example, the block copolymer may be present in the composition at a concentration ranging from 1% wt / wt to 2% wt / wt to 5% wt / wt to 10% wt / wt to 20% wt / wt to 30% wt / wt to 40% wt / wt to 50% wt / wt.

[0044] In some embodiments, the compositions of the present disclosure further comprise at least one anionic polymer comprising one or more groups selected from sulfonate, sulfate, phosphate, phosphonate, or carboxylate groups, which are negatively charged at pH 7, preferably negatively charged at a pH greater than 4 or 5, and in some cases negatively charged at a pH greater than 2. Such anionic polymers may be combined / mixed with the block copolymer to further adjust the properties of the gel compositions described herein, including gel strength, flexibility, cohesion, flowability, and / or gel stability, among other properties. Specific examples of anionic polymers include sulfonate polymers such as poly(2-acrylamido-2-methylpropanesulfonate) (polyAMPS) or polystyrene sulfonate, polyphosphates, poly(carboxylic acids) such as poly(acrylic acid) or poly(methacrylic acid), and negatively charged polysaccharides including alginates, hyaluronates, pectins, carrageenans, gellan gum, gum arabic, guar gum, or xanthan gum. The anionic polymers may be provided in salt form, for example, in particular, sodium or potassium salt form. In some embodiments, the anionic polymer can have a number average molecular weight in the range of 1,000 Da to 5,000,000 Da, for example, any range of 1,000 Da to 2,000 Da to 5,000 Da to 10,000 Da to 20,000 Da to 50,000 Da to 100,000 Da to 200,000 Da to 500,000 Da to 1,000,000 Da to 2,000,000 Da to 5,000,000 Da.

[0045] In some embodiments, the at least one anionic polymer is present in an amount ranging from 0.1% wt / wt or less to 50% wt / wt or more by weight of the composition, which may be a liquid composition, e.g., an aqueous liquid composition. For example, the at least one anionic polymer may be present in any of the following amounts by weight of the composition: 0.1% wt / wt, 0.2% wt / wt, 0.5% wt / wt, 1% wt / wt, 2% wt / wt, 5% wt / wt, 10% wt / wt, 20% wt / wt, 30% wt / wt, 40% wt / wt, 50% wt / wt.

[0046] In some embodiments, the molar ratio of positively charged amino groups in the DBA block (assuming 100% ionization) to negatively charged groups in the anionic polymer (assuming 100% ionization) ranges from 0.1:1 to 10:1, typically from 0.5:1 to 2:1, and more typically from 1:1 to 1:1.5.

[0047] In some embodiments, the composition can further comprise at least one imaging agent.Examples of imaging agents include radiocontrast agents, imageable radioisotopes, fluorescent dyes, magnetic resonance imaging (MRI) contrast agents, ultrasound contrast agents and near-infrared (NIR) imaging contrast agents.Specific examples of radiocontrast agents include metal particles such as tantalum, tungsten, rhenium, niobium, molybdenum and their alloy particles, and the metal particles can be spherical or non-spherical. Specific examples of radiological contrast agents further include non-ionic radiological contrast agents (e.g., iohexol, iodixanol, ioversol, iopamidol, ioxilan, or iopromide), ionic radiological contrast agents (e.g., diatrizoate, iothalamate, metrizoate, or ioxaglate), and iodized oils, including ethiodized poppyseed oil (available as Lipiodol®). Further specific examples of imaging agents include (a) fluorescent dyes, such as fluorescein, indocyanine green, or fluorescent proteins (e.g., green, blue, cyan fluorescent proteins); (b) Gd (III) , Mn (II) , Fe (III)(c) contrast agents for use with ultrasound imaging, including organic and inorganic echogenic particles (i.e., particles that result in an increase in reflected ultrasound energy) or organic and inorganic echolucent particles (i.e., particles that result in a decrease in reflected ultrasound energy); (d) contrast agents for use with magnetic resonance imaging (MRI), including contrast agents containing elements that form paramagnetic ions such as gadolinium ion chelated with diethylenetriaminepentaacetic acid; (e) contrast agents for use with ultrasound imaging, including organic and inorganic echogenic particles (i.e., particles that result in an increase in reflected ultrasound energy) or organic and inorganic echolucent particles (i.e., particles that result in a decrease in reflected ultrasound energy); (e) contrast agents for use with ultrasound imaging, including organic and inorganic echogenic particles (i.e., particles that result in an increase in reflected ultrasound energy), which can be selected to impart near-infrared fluorescence to the hydrogels of the present disclosure, allowing for deep tissue imaging and device imaging; Contrast agents for use with near-infrared (NIR) imaging that enable isotopic marking, for example, NIR-sensitive nanoparticles such as gold nanoshells, carbon nanotubes (e.g., nanotubes derivatized with hydroxyl or carboxyl groups, e.g., partially oxidized carbon nanotubes), dye-containing nanoparticles such as dye-doped nanofibers and dye-encapsulated nanoparticles, and semiconductor quantum dots, and NIR-sensitive dyes such as cyanine dyes, squaraines, phthalocyanines, porphyrin derivatives, and boron dipyrromethane (BODIPY) analogs, among others; and (e) NIR-sensitive dyes such as cyanine dyes, squaraines, phthalocyanines, porphyrin derivatives, and boron dipyrromethane (BODIPY) analogs, among others. 99m Tc, 201 Th, 51 Cr, 67 Ga, 68 Ga, 111 In, 64 Cu, 89 Zr, 59 Fe, 42 K. 82 Rb, 24 Na, 45 Ti, 44 Sc, 51 Cr and 177 Imaging radioisotopes include Lu.

[0048] In some embodiments, the at least one imaging agent is present in an amount ranging from 1% wt / wt or less to 50% wt / wt or more by weight of the composition, which may be a liquid composition, e.g., an aqueous liquid composition. For example, the at least one imaging agent may be present in the composition at a concentration ranging from 1% wt / wt to 2% wt / wt to 5% wt / wt to 10% wt / wt to 20% wt / wt to 30% wt / wt to 40% wt / wt to 50% wt / wt.

[0049] In some embodiments, the composition may further comprise one or more therapeutic agents, examples of which include small molecule therapeutic agents (defined herein as therapeutic agents having a molecular weight of less than 2000 g / mol, typically less than 1500 g / mol, and more typically less than 1000 g / mol), biomolecules (e.g., polypeptides, including proteins and protein fragments such as antibodies and antibody fragments and oligopeptides, and polynucleotides and oligonucleotides, including nucleic acids and nucleic acid analogs such as deoxyribonucleic acid, ribonucleic acid, peptide nucleic acid, and fragments thereof), and radioisotopes.

[0050] In some embodiments, the one or more therapeutic agents are present in an amount ranging from 0.001% wt / wt (10 ppm) or less to 80% wt / wt or more by weight of the composition, which may be a liquid composition, e.g., an aqueous liquid composition. For example, the one or more therapeutic agents may be present in the composition at a concentration ranging from 0.001% wt / wt to 0.002% wt / wt to 0.005% wt / wt to 0.01% wt / wt to 0.02% wt / wt to 0.05% wt / wt to 0.1% wt / wt to 0.2% wt / wt to 0.5% wt / wt to 1% wt / wt to 2% wt / wt to 5% wt / wt to 10% wt / wt to 20% wt / wt to 50% wt / wt to 80% wt / wt.

[0051] Specific examples of therapeutic agents include, among others, anti-angiogenic agents, cytotoxic agents, chemotherapeutic agents, checkpoint inhibitors, immunomodulatory cytokines, T cell agonists, and STING (stimulator of interferon genes) agonists.

[0052] Examples of therapeutic agents include, among others, checkpoint inhibitors including inhibitors of PD-1 binding to PD-L1, inhibitors of CTLA-4 binding to CD80 and / or CD86, inhibitors of TIGIT binding to CD-112, and inhibitors of LAG-3 binding to MHC class II molecules; inhibitors of PD-1 (e.g., pembrolizumab, nivolumab dombanalimab, etc.), PD-L1 (e.g., atezolizumab, avelumab, durvalumab, etc.), LAG-3 (e.g., leratolimab, etc.), TIM- antibodies or antigen-binding fragments thereof that bind to CD3 (e.g., LY3321367, MBG453, TSR-022, etc.), TIGIT (e.g., etidilimab, tiragolumab, vibostolimab, etc.), or CTLA-4 (e.g., ipilimumab tremelimumab, etc.); CD3, CD19, CD20, CD22, CD52, CD79B, CD30, CD33, CD38, CD52, CD79B, HER2, EGFR, VEGF, VEGFR2, EPCAM / CD3, GD2, IL-6, RANKL, antibodies or antigen-binding fragments thereof that bind to SLAMF7, CCR4, PDGFRα, Nectin-4, or TROP2; immunomodulatory cytokines such as IL-2, IL-12, IL-15, IL-23, interferon gamma (IFN-γ), and gm-CSF (granulocyte colony-stimulating factor); TLR3 agonists (e.g., polyinosinic acid:polycytidylic acid, double-stranded RNA, etc.), TLR7 agonists (e.g., TMX-202, gardikimod, imiquimod, etc.), TLR8 agonists (e.g., cyclosporin ... Examples of suitable agonists include T cell agonists such as VTX-2337, TLR7 / 8 agonists (e.g., MEDI9197, R848, resiquimod, etc.), TLR9 agonists (e.g., lefitolimod (MGN1703), tilsotolimod, CpG oligodeoxynucleotides (e.g., agatolimod), etc.); and STING agonists such as GSK532, cyclic dinucleotides (e.g., cyclic guanosine monophosphate adenosine monophosphate), CRD5500 (LB-061), E7766, ADU-S100, SB11285 MSA2, MK1454, and TTI-10001.

[0053] Examples of therapeutic agents also include camptothecins (e.g., irinotecan, topotecan, and exatecan) and anthracyclines (e.g., doxorubicin, daunorubicin, idarubicin, and epirubicin), anti-angiogenic agents (e.g., vascular endothelial growth factor receptor (VEGFR) inhibitors (e.g., axitinib, bortezomib, bosutinib, canertinib, dovitinib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, lestaurine, levothyrox ... anticoagulants (e.g., vinblastine, vinorelbine, and vincristine), aromatase inhibitors (e.g., anastrazole), platinum drugs (e.g., cisplatin, oxaliplatin, carboplatin, and miriplatin), nucleoside analogs (e.g., 5-F U, cytarabine, fludarabine, and gemcitabine), paclitaxel, docetaxel, mitomycin C, mitoxantrone, bleomycin, pinyagumycin, abiraterone, amifostine, buserelin, degarelix, folinic acid, goserelin, lanreotide, lenalidomide, letrozole, leuprolide, octreotide, tamoxifen, triptorelin, bendamustine, chlorambucil, dacarbazine, melphalin, procarbazine anti-cancer drugs include cefotaxime, temozolomide, rapamycin (and analogs such as zotarolimus, evaronigib, umirolimus, sirolimus, etc.), antimetabolites (e.g., 5-fluorouracil), multi-tyrosine kinase inhibitors (e.g., sorafenib, sunitinib, regorafenib, brivanib, dasatinib, bosutinib, erlotinib, gefitinib, imatinib, and vandetinib), methotrexate, pemetrexed, or raltitrexed.

[0054] Therapeutic radioisotopes include: 177 Lu, 90 Y, 131 I, 89 Sr, 153 Sm, 223 Ra, 224 Ra, 211 At,225 Ac, 227 Th, 212 Bi, 213 Bi, and / or 212 These include, but are not limited to, Pb.

[0055] In some embodiments, the compositions described herein may contain therapeutic agents that are charged and / or uncharged at physiological pH. Charged therapeutic agents may be electrostatically retained within a gel composition and subsequently released therefrom by an ion exchange mechanism (e.g., when the composition further comprises an anionic polymer containing one or more negatively charged groups selected from sulfonate, sulfate, phosphate, phosphonate, or carboxylate groups). Charged therapeutic agents electrostatically retained in the gel composition may elute from the gel composition in an electrolyte medium (e.g., saline (0.90% w / v NaCl)) or in vivo (e.g., in blood or tissue) to provide sustained release of the therapeutic agent over hours, days, or even weeks. Uncharged therapeutic agents in the gel composition may also elute from the gel composition in vivo. This may be particularly advantageous, for example, when rapid elution or a "burst effect" is desired, e.g., for rapid therapeutic agent delivery to tissues, or when the low solubility of the therapeutic agent under physiological conditions, rather than ionic interactions, determines the release profile.

[0056] Embodiments of the present disclosure also relate to medical compositions corresponding to or formed from the liquid compositions of any of the preceding embodiments. For example, as previously described, such liquid compositions may be used for embolization, fiducial markers, tissue fillers, tissue spacers, and in vivo formation of therapeutic agent depots.

[0057] Some embodiments of the present disclosure further relate to medical treatments using the liquid compositions described herein.For example, in some embodiments, the medical treatment is a method of tissue embolization, comprising delivering the liquid composition into one or more blood vessels that supply nutrients to tissue.Such treatments can be used to treat various conditions, including the treatment of arteriovenous malformations, the treatment of gastrointestinal bleeding, the treatment of endoleaks, the filling of aneurysms, the treatment of bleeding caused by disease or trauma, the treatment of solid tumors (particularly hypervascular tumors such as liver, prostate, kidney, brain, colon, bone and lung tumors), and benign hyperplasia conditions (for example, the treatment of benign prostatic hyperplasia or the treatment of uterine fibroids).

[0058] In some embodiments, the medical procedure is a method of local or systemic therapeutic agent release comprising delivering (e.g., by injection, spraying, etc.) a liquid composition described herein to a patient (e.g., onto, within, between the patient's tissues, etc.).

[0059] In some embodiments, the medical procedure is a therapeutic method comprising delivering (e.g., by injection, spraying, etc.) a liquid composition described herein into or onto a tumor of a patient, wherein the therapeutic agent is released into the tumor.

[0060] In some embodiments, the medical procedure is a method of spacing a first tissue from a second tissue, comprising delivering (e.g., injecting, etc.) a liquid composition described herein between the first tissue and the second tissue (e.g., between prostate tissue and rectal tissue).

[0061] In some embodiments, the medical procedure is a therapeutic method comprising delivering (e.g., by injection, spraying, etc.) a liquid composition described herein into a patient as a fiducial marker.

[0062] In still further embodiments, the present disclosure relates to the use of the liquid compositions described herein in the manufacture of medicaments for the treatment of various diseases and conditions, including the treatment of arteriovenous malformations, the treatment of gastrointestinal bleeding, the filling of aneurysms, the treatment of solid tumors (particularly hypervascular tumors such as tumors of the liver, prostate, kidney, brain, colon, bone, and lung), and the treatment of benign hyperplastic conditions such as benign prostatic hyperplasia or uterine fibroids.

[0063] The present disclosure also relates to the use of any of the therapeutic agents described herein in the manufacture of a medicament for the treatment of such diseases and conditions, wherein the therapeutic agent is incorporated into a liquid or gel composition described herein. The present disclosure also relates to the use of any of the therapeutic agents herein in the treatment of such diseases and conditions, wherein the therapeutic agent is incorporated into a liquid or gel composition described herein. The liquid compositions may be used, particularly when the liquid composition is delivered by a transcatheter route, by injection, by implantation, by spraying, etc.

[0064] The foregoing embodiments may include one or more poly(N-isopropylaminoacrylamide) blocks and one or more poly(2-(di-(C 1~5 ) alkylamino)(C 1~5 However, in any of the embodiments described herein, the one or more poly(2-(di-(C 1~5 ) alkylamino)(C 1~5It should be understood that instead of the poly(N,N-dimethylaminoethyl methacrylate) block, any of the following blocks may be used: one or more poly(N,N-diethylaminoethyl methacrylate) blocks, one or more poly(2-(tetramethyleneimino)ethyl methacrylate) blocks, one or more poly(2-(pentamethyleneimino)ethyl methacrylate) blocks, one or more poly(2-(hex ... (2-(piperidino)ethyl methacrylate)) block, one or more poly(dioctylaminoethyl acrylate) blocks, one or more poly(piperidylethyl acrylate) blocks, one or more poly(N,N-dimethylaminoethyl acrylate) blocks, one or more poly(N,N-diethylaminoethyl methacrylate) blocks, one or more poly(N,N-diisopropylaminoethyl acrylate) blocks, one or more poly(N,N-di(n-butyl)-aminoethyl acrylate) blocks, one or more poly(2-(tetramethylene iodomethyl methacrylate) blocks, one or more poly(dioctylaminoethyl acrylate) blocks, one or more poly(piperidylethyl acrylate) blocks, one or more poly(2-(tetramethylene iodomethyl methacrylate) blocks, one or more poly(dioctylaminoethyl acrylate) blocks, one or more poly(piperidylethyl acrylate) blocks, one or more poly(dioctylaminoethyl acrylate) blocks, one or more poly(piperidylethyl acrylate) blocks, one or more poly(2-(tetramethylene iodomethyl methacrylate) blocks, one or more poly(dioctylaminoethyl ... one or more poly(2-(pentamethyleneimino)ethyl acrylate) blocks, one or more poly(2-(hexamethyleneimino)ethyl acrylate) blocks, one or more poly(N,N-dimethylaminoethyl methacrylamide) blocks, one or more poly(N,N-diethylaminoethyl methacrylamide) blocks, one or more poly(N,N-diisopropylaminoethyl methacrylamide) blocks, one or more poly(N,N-di(n-butyl)aminoethyl methacrylamide) blocks, one or more poly (2-(tetramethyleneimino)ethyl methacrylamide) block, one or more poly(2-(pentamethyleneimino)ethyl methacrylamide) blocks, one or more poly(2-(hexamethyleneimino)ethyl methacrylamide) blocks, one or more poly(2-(piperidino)ethyl methacrylamide) blocks, one or more poly(dioctylaminoethyl acrylamide) blocks, one or more poly(piperidylethyl acrylamide) blocks, one or more poly(N,N-dimethylaminoethyl acrylamide) blocks, one or more poly(N,N-diethylaminoethylacrylamide) blocks, one or more poly(N,N-diisopropylaminoethylacrylamide) blocks, one or more poly(N,N-di(n-butyl)aminoethylacrylamide) blocks, one or more poly(2-(tetramethyleneimino)ethylacrylamide) blocks, one or more poly(2-(pentamethyleneimino)ethylacrylamide) blocks, or one or more poly(2-(hexamethyleneimino)ethylacrylamide) blocks.

[0065] experiment A specific example of an ABA triblock copolymer composition is presented here (see Figure 1), in which the ABA triblock copolymer contains a pH-responsive central poly(2-(dibutylamino)ethyl methacrylate) block and two thermo-responsive poly(N-isopropylaminoacrylamide) terminal blocks. The ABA triblock copolymer was synthesized by using RAFT (reversible addition-fragmentation chain transfer radical polymerization) technology, starting with the polymerization of N-isopropylacrylamide (NIPAAM) initiated by 4,4'-azobis(4-cyanovaleric acid) (ACVA) and the chain transfer agent 4-((((2-carboxyethyl)thio)carbonothioyl)thio)-4-cyanopentanoic acid (CETCPA). After synthesizing the first block, protonated 2-(dibutylamino)ethyl methacrylate monomer (DBA) was used to polymerize the DBA block, followed by copolymerization of the third block of NIPAAM (see Figure 4). Methanol was used as the reaction solvent.

[0066] Without being bound by theory, it is believed that the resulting NIPAAM-DBA-NIPAAM copolymer solution forms a physically crosslinked hydrogel through hydrophobic interactions at physiological conditions, pH 7 and 37°C. In this regard, at ambient temperature (20-25°C) and pH 5-6, the resulting aqueous solution of NIPAAM-DBA-NIPAAM copolymer is in a free-flowing liquid form because both the NIPAAM and DBA blocks are water-soluble. When mixed with polyAMPS, the positively charged amine groups of the DBA block complex with the negatively charged sulfonate groups of polyAMPS, generating a coacervate viscous liquid phase (schematically shown in Figure 3A). This viscous liquid is relatively easily deliverable through a 2.7-2.8 Fr catheter using a 1 mL or 3 mL syringe. During catheter delivery, the temperature of the blood vessel in which the catheter is located is approximately 37°C, resulting in an increase in the temperature of the complex liquid to approximately 30-37°C. The sol-gel transition of the NIPAAm block occurs due to the increased hydrophobicity of NIPAAm at higher temperatures, and a physically crosslinked, "flowable" hydrogel structure composed of mixed micelles and complexes is formed (schematically shown in Figure 3B). The micelle core is NIPAAm, and the corona is balanced by the hydrophilic, protonated DBA block, which interacts with polyAMPs. Then, when this gel is placed in a physiological solution at pH 7-7.4 (e.g., within the vasculature), partial DBA deprotonation occurs because DBA has a pKa = 5. The hydrogel structure is further enhanced by the increased hydrophobicity of the DBA block, and the hydrogel strength and viscosity increase significantly (schematically shown in Figure 3C).

[0067] Example 1. pNIPAAM 300 Synthesis of CETCPA (0.0272 g, 0.09 mmol), NIPAAM (3 g, 26.51 mmol, NIPAAM / CPATTC molar ratio = 300), and ACVA (5 mg, 0.02 mmol, ACVA / CETCPA molar ratio = 0.2) were added to a round-bottom flask (RBF) and dissolved in 3 mL of methanol. The RBF was sealed with a rubber stopper, and the reaction mixture was degassed with N for a minimum of 30 minutes. The degassing step was performed by bubbling N directly into the reaction mixture using a short needle (in the stopper as an outlet) and a long needle (as an inlet) while maintaining the RBF under constant stirring in an ice bath. After degassing, the RBF was placed in a preheated oil bath at 70 °C, and the reaction was allowed to proceed for 24 h under constant magnetic stirring. The reaction was stopped by opening the RBF to the air and placing the RBF in an ice bath. An aliquot (50 μL) of the reaction mixture was 1 A sample was taken for H NMR analysis (see Figure 5A). No purification was performed. Proton NMR analysis of the mixture indicated that >98% of the NIPAAM monomer had reacted.

[0068] Example 2. pNIPAAM 300 -pDBA 100 Synthesis of 2-(dibutylamino)ethyl methacrylate (DBA) (2.13 g, 8.84 mmol, DBA / pNIPAAM) 300 DBA (molar ratio = 100) and deionized water (2 mL) were mixed in a RBF and stirred with a magnetic stirrer. The RBF was placed in an ice bath while a 25 wt% HCl solution (1.151 mL, DBA / HCl molar ratio = 1) was added and maintained at room temperature under constant stirring until all DBA was dissolved. The pH of the mixture was adjusted to 6 with 1 M NaOH solution (0.673 mL). The protonated DBA solution was then added to the pNIPAAM prepared in the previous step. 300 The solution was then transferred to the RBF containing ACVA (5 mg, 0.02 mmol, ACVA / pNIPAAM). 300 The reaction mixture was degassed with N2 for 30 minutes, and then the RBF was placed in a preheated oil bath at 70 °C for 24 hours. An aliquot (50 μL) of the reaction mixture was added to the RBF. 1 It was removed for H NMR analysis (see Figure 5B) and no purification was performed.

[0069] Example 3. pNIPAAM 300 -pDBA 100 -pNIPAAM 300 Synthesis of pNIPAAM 300 -pDBA 100 RBF containing NIPAAM (3 g, 26.51 mmol, NIPAAM / pNIPAAM) 300 -pDBA 100 Molar ratio = 300) with ACVA (5 mg, 0.02 mmol, ACVA / pNIPAAM 300 -pDBA 100 The reaction mixture was degassed with N2 for a minimum of 30 minutes, after which the RBF was placed in a preheated oil bath at 70 °C for 24 hours. An aliquot (50 μL) of the reaction mixture was 1 The purified sample was then purified by dialysis. 1 The copolymers were analyzed by H NMR analysis (see Figure 5D). The synthesis of the triblock copolymer is shown schematically in Figure 4. A list of copolymers synthesized using this technique is shown in Table 1.

[0070] [Table 1]

[0071] Example 4. Synthesis of NIPAAM-DEA-NIPAAM triblock copolymer The triblock copolymer was synthesized by the ATRP method. 0.11 g (1 equiv.) of diethyl meso-2,5-dibromoadipate (initiator), 5.6 g (100 equiv.) of DEA (2-(diethylamino)ethyl methacrylate) monomer, 0.138 g (2 equiv.) of HMTETA (1,1,4,7,10,10-hexamethyltriethylenetetramine) catalyst, and 0.086 g (2 equiv.) of copper(I) bromide were placed in a 250 mL three-neck round-bottom flask with 6 mL of anhydrous methanol. The mixture in the flask was frozen with liquid nitrogen, degassed by three freeze-thaw cycles, and then polymerized overnight in an oil bath at 70 °C. The resulting DEA polymer was purified by passing it through a silica gel column to remove the copper catalyst. The polyDEA was further dried under vacuum at 40 °C for 24 h.

[0072] 2.5 g of the resulting polyDEA macromer was mixed with 6.0 g of NIPAAm monomer in 15 mL of anhydrous methanol, followed by degassing with nitrogen for 50 minutes. Under a nitrogen atmosphere, 0.038 g (2 equivalents) of the catalyst copper(I) bromide and 0.068 g (2 equivalents) of Me4Cyclam (1,4,8,11-tetramethyl-1,4,8,11-tetraazacyclotetradecane) were added at ambient temperature. The reaction was stirred overnight under nitrogen. After completion, the solution was passed through a silica gel column using MeOH as the eluent to remove the catalyst. The solvent was removed by rotary evaporation, and the polymer was further dried under vacuum at 40 °C for 24 hours.

[0073] Example 5. Typical procedure for the preparation of polymeric emboli by mixing triblock copolymers with polyAMPS As a typical procedure for preparing the composite hydrogel, to make a 20% wt / wt polymer solution, 2 g of triblock copolymer (Sample 4, Table 1) was dissolved in 8 g of deionized water by repeatedly placing the vial of solution in either an ice-water bath or a refrigerator (2-8 °C) for 1-2 hours, followed by roller mixing for 1 hour until most of the solid polymer was dissolved. The solution was then kept in the refrigerator overnight and roller mixed again for 2 hours to obtain a homogeneous solution.

[0074] This solution was homogeneously mixed with 0.9 g of tantalum powder (20% solids) in a 10 mL syringe. Air bubbles were removed by gently tapping the syringe. PolyAMPS sodium form was prepared by slowly adding NaOH powder to a poly(2-acrylamido-2-methyl-1-propanesulfonic acid) solution (MW approximately 2 million Da, 15% concentration) while stirring to adjust the pH to approximately pH 4. To provide a charge ratio of approximately 1:1.5, 0.54 g of polyAMPS in a second 10 mL syringe was mixed with the tantalum polymer suspension through a three-way stopcock to form a homogeneous mixture. The mixture was then pumped into one 10 mL syringe and capped for steam sterilization at 121 °C for 30 minutes. The suspension was repeatedly mixed by exchanging it with another syringe through the three-way stopcock at room temperature. Finally, the suspension was dispensed into 1 mL syringes for catheter delivery. The final composition contained 11.1% wt / wt of triblock copolymer, 3.7% wt / wt of polyAMPS, and 20% wt / wt of tantalum. Figure 6 shows the hydrogel formed after injecting the composition through an 18G needle into PBS buffer at 37°C. The PBS buffer composition was 140 mM NaCl, 10 mM phosphate buffer, and 3 mM KCl, pH 7.4.

[0075] A similar process was used to prepare a representative composite gel of NIPAAM-DEA-NIPAAM triblock copolymer and polyAMPS. Example 6. Rheological study of composite gels with different charge ratios between DBA blocks and polyAMPS A NIPAAM-DBA-NIPAAM copolymer solution was prepared under slightly acidic conditions to fully protonate the DBA block. The pH of the resulting solution was measured and found to be approximately in the pH range of 5-6. When a polyAMPS solution was mixed with the copolymer solution via two-syringe mixing, a viscous coacervate solution was formed at room temperature. The rheological properties of the solution could be altered by controlling the charge ratio of DBA to polyAMPS in the composition.

[0076] Figure 7 shows the rheological behavior of NIPAAM300-DBA100-NIPAAM300 composite gels with different charge ratios between DBA and polyAMPS, specifically 1:0, 1:1, and 1:1.5. Tantalum powder was not used in this study. Figure 7 shows that without the addition of AMPS (1:0 ratio), there is no charge-charge interaction, resulting in the formation of soft gels. In solution at low temperatures (<30°C), the copolymer hydrogels with a 1:1.5 ratio behaved more like soft solids (G' < 100 Pa) compared to the 1:1 ratio gels, which were relatively soft and slightly stiffer. This may be due to the contribution of the extra polyAMPS chains to lower both the storage and loss moduli. At elevated temperatures, approximately 37°C, all gels were more solid-like (G' > G''), with the 1:1 ratio gels being stiffer compared to the 1:1.5 ratio gels. For the sample containing NIPAAM400-DBA200-NIPAAM400, the gels with a ratio of 1:1 and 1:1.5 showed almost identical behavior, which may be explained by the high molecular weight and strong chain entanglement.

[0077] Example 7. Effect of DBA and NIPAAM chains on the rheological properties of temperature- and pH-responsive composite gels Figure 8 shows the storage and loss moduli of various pNIPAAM-b-pDBA-b-pNIPAAMa triblock copolymer samples over a temperature gradient. The results suggest that increasing the chain length of the NIPAAm block tends to increase the storage modulus of the hydrogel at elevated temperatures, approximately 37 °C. Tantalum powder was not used in this study. As the temperature increased from 33 to 37 °C, the storage modulus of the DBA100 copolymer gel increased from 4 kPa to 7 kPa, and from NIPAAm200 to NIPAAm300, respectively. The storage modulus of the DBA200 copolymer gel increased from approximately 10 kPa to 11 kPa with the change from NIPAAm300 to NIPAAm400, respectively.

[0078] As can be seen from the graph in Figure 8, at temperatures below 30°C, the composite gels of the short-chain copolymers exhibited more liquid-like behavior, with loss moduli greater than the storage modulus (10-50 Pa). As molecular weight increased to (Sample 7, Table 1), the storage and loss moduli were nearly identical, between 200 and 300 Pa, suggesting a more solid-like composite gel. This measurement is consistent with the observation that Samples 3 and 4 (Table 1) were relatively easy to deliver, while Samples 6 and 7 (Table 1) were much stiffer gels that required greater force for catheter delivery.

[0079] Without wishing to be bound by any theory, the role played by the DBA block in hydrogel formation appears to be a complex with the DBA component interacting with polyAMPS at pH below 7, while the hydrophobic portion enhances gel strength along with NIPAAM at 37°C and pH 7. Figure 8 shows two copolymers, DBA100 and DBA200, with the same NIPAAM300 length. The DBA200 copolymer has an increased storage modulus compared to DBA100.

[0080] To study the effect of DBA length, copolymers with DBA300 and DBA400 were synthesized and related composite hydrogel samples were prepared. Table 2 lists the sample morphology and properties. Samples 4 and 6 (Table 2) both have NIPAAM300 blocks with either 100 or 200 DBA blocks, while samples 3, 8, and 9 have NIPAAM200 blocks with 100–400 DBA blocks. In general, gel samples with shorter DBA chains, between 100 and 200 units, are more homogeneous and liquid-like. The gels are relatively easy to deliver through a 2.7–2.8 Fr catheter.

[0081] [Table 2]

[0082] Samples with longer DBA units (i.e., 300-400 units) immediately formed a composite precipitate when mixed with polyAMPS. The composite gels were found to be difficult to mix, even during the sample preparation stage. The gels tended to break down into small particles and then aggregate, causing blockages in the syringe. Rheological studies using NIPAAM400-DBA300-NIPAAM400 mixed with polyAMPS were not performed because a uniform gel could not be produced.

[0083] Example 8. Effect of pH change on composite gel properties The composite hydrogel in this example, composed of protonated NIPAAM-DBA-NIPAAM triblock copolymer and polyAMPS, had a pH range of 5-6 before and after delivery. After delivery to a physiological environment, the DBA block began to partially deprotonate, becoming hydrophobic, further enhancing the hydrophobicity of the composite gel combined with NIPAAM at 37 °C. To measure the gel modulus, preliminary rheological studies were performed using an oscillatory method. To understand the effect of pH change on gel properties, initial studies were performed on the gel at 37 °C, followed by the addition of PBS buffer to the test cell. The cell was fabricated from a 3D-printed plastic cylinder with a sealed O-ring at the bottom, connected to the rheometer's test plate. To study the gel behavior at pH 5-6, the gel was first placed under a 25 mm parallel plate geometry and subjected to oscillatory testing in air, mimicking the pre-delivery of the gel in a catheter. Then, pH 7.4 PBS buffer was added to the cell to induce a gel pH change that mimicked the gel after delivery to a physiological environment. Changes in storage and loss moduli were recorded to demonstrate gel behavior before and after delivery.

[0084] Figure 9 shows the test results for two composite gels: NIPAAM300-DBA100-NIPAAM300 (Sample 4, Table 2) and NIPAAM400-DBA200-NIPAAM400 (Sample 7, Table 2), copolymer samples with polyAMPS at a charge ratio of 1:1.5. The increase in elastic modulus shown in Figure 9 demonstrated that deprotonation of the DBA moiety can enhance the hydrophobic interactions of the hydrogel network formed at high temperatures. After adding PBS buffer, the increase in elastic modulus observed in both samples was relatively small, likely because contact between the gel and the PBS solution initially occurred only at the edges of the geometry, whereas deprotonation of the internal gel may require longer time. It is also possible that the higher fraction of NIPAAM in the polymer formed a more hydrophobic barrier that slowed the diffusion of PBS into the sample disk under the plate. Therefore, the observed increase in elastic modulus was much lower than that observed in vivo and is likely due to the very small contact area at the edges of the sample disk.

[0085] Rheological studies confirmed the thermoresponsive nature of the polymer by increasing the temperature from 15 to 40 °C, and the sol-gel transition of the polymer solution was observed at approximately 32–34 °C. These were measured at a fixed shear strain of 0.1% and an angular frequency of 10 rad / s. The effect of pH on the hydrogel's elastic modulus was studied by adding PBS to the top of the polymer solution trapped under a 25 mm flat geometry at 37 °C. The same shear strain and angular frequency were applied.

[0086] Example 9. Comparison of NIPAAM-DEA-NIPAAM triblock copolymer with NIPAAM-DBA-NIPAAM triblock copolymer Compared to the triblock copolymer NIPAAM200-DBA100-NIPAAM200, the DEA block of NIPAAM200-DEA100-NIPAAM200 is less hydrophobic due to the four-carbon difference between the diethylamino and dibutylamino groups. Figure 10 shows the effect of this difference on the rheology of composite gels formed with polyAMPS. The NIPAAM-DEA-NIPAAM composite gel was more solid-like, with G' > G''. Although it was temperature-sensitive, its storage modulus (G' approximately 200 Pa) at approximately 37°C did not increase significantly compared to the storage modulus at 25°C, suggesting a weak gel. Visual inspection of the gel also indicated a uniform mixture and complexation between the DEA block and polyAMPS (Table 2). Sedimentation and flow model tests confirmed the rheological test data, i.e., gel fragment formation during stirring and passage through the pores of the flow model. Furthermore, the DEA block has a pKa of 7.4, suggesting that the NIPAAM-DEA-NIPAAM copolymer does not exhibit significant pH responsiveness under physiological conditions.

[0087] Example 11. Precipitation test of tantalum mixed composite gels with different compositions Samples of copolymer-polyAMPS composite gels mixed with 20% tantalum powder were first tested in PBS at 37°C by delivering the solution through an 18-gauge needle into the PBS and observing precipitation. Samples 3, 4, 6, and 7 were tested with two levels of polyAMPS at charge ratios of 1:1 or 1:1.5. The compositions contained 9.2–12.9% wt / wt of triblock copolymer, 2.4–4.0% wt / wt (1:1 ratio) or 3.2–5.1% wt / wt (1:1.5 ratio) of polyAMPS, and 20% wt / wt of tantalum. The test results are shown in Table 3. Samples 13, 14, and 15 were formulated with polyAMPS at charge ratios of 1:1, 1:1.2, 1:1.5, and 1:2. Tantalum powder and 1.0–1.2 M NaCl solution were also added to the formulations. The compositions tested contained 5.0-7.3% wt / wt triblock copolymer, 5.0-7.7% wt / wt polyAMPS, and 20% wt / wt tantalum powder. The addition of NaCl shielded charge-charge interactions, allowing for more distal delivery of the formulation. Upon diffusion of concentrated NaCl from the fluid, the coacervated gel solidified and embolized small blood vessels.

[0088] [Table 3-1]

[0089] [Table 3-2]

[0090] All eight samples were stringy in gel morphology, suggesting that the gel had already begun to form within the needle before delivery. Samples 3 and 4 had fewer gel particles / fragments in PBS, demonstrating greater cohesion. Sample 4 appeared to have improved cohesion compared to Sample 3. Additionally, gels with higher polyAMPS (1:1.5 ratio) were softer compared to samples with a 1:1 ratio, consistent with other rheological test results. The samples withstood vigorous vial shaking at approximately 37°C, and no broken fragments were observed. When the PBS temperature dropped below 30°C, the gel began to disintegrate, and tantalum powder leached out of the gel. Meanwhile, the solution became translucent, likely due to dispersed micelle formation from the NIPAAM-DBA-NIPAAM block copolymer.

[0091] Samples 6 and 7, which have longer DBA and NIPAAM chains, appeared less cohesive when delivered in PBS buffer at 37°C, and large fragments of polymer and small amounts of tantalum powder were found in solution even at temperatures above 35°C. Similar to Samples 3 and 4, gels with longer DBA and NIPAAM chains result in the formation of smaller fragments and dispersed tantalum powder when the temperature of the PBS is reduced below 30°C.

[0092] Based on the test results, Sample 4 had higher gel strength and cohesiveness even after vigorously shaking the vial, but had a storage modulus of 6 kPa, suggesting a relatively rigid gel.

[0093] Example 12. Tantalum mixed composite gel delivered in a flow model Solutions of the NIPAAM-DBA-NIPAAM triblock copolymer prepared at low temperatures and pH 5-6 could also be easily delivered through a catheter as a liquid embolic composition (Figure 11). During catheter delivery in a PBS flow model system, the polymer solution tended to begin gelling within the catheter as the temperature increased from ambient to 37 °C. Nevertheless, the gel remained pushable without excessive force, which allowed for rapid gelation with adequate gel strength (i.e., without shearing into fragments) after entering the bloodstream. As saline began to exchange with water in the gel, the pH of the gel rose to pH 7, causing deprotonation of DBA, enhancing gel strength and resulting in favorable long-term gel stability.

[0094] Radiopaque contrast agents and tantalum powder can be added to the composition to facilitate fluoroscopically guided surgical procedures. For example, liquid contrast agents, such as iodized oils such as iodized poppy seed oil, can also be used to confirm the quality of embolization. This can be easily achieved, for example, by using a three-way stopcock attached to a syringe at the proximal side of the catheter so that the contrast agent can be injected after embolization is completed.

[0095] Example 13. Preclinical testing of the composite gel in porcine kidney and liver models To evaluate the deliverability, handling, embolization performance, and visibility of the composite gel in a porcine model, Sample 4 (Table 3) and a reference sample (containing gelatin, laponite, and tantalum mixed with water) were delivered into the renal and hepatic arteries.

[0096] An 18% gel sample was first autoclaved in a 3 mL syringe at 121 °C for 30 minutes. Testing showed that the processed gel sample maintained its thermo- and pH-responsive gelation properties and was not significantly different from the pre-autoclaved sample. Preliminary observations from physician user experience indicated that sample delivery was easy and without difficulty. The gel exiting the catheter tip appeared as a coil-like string with a proximal distribution. Initial embolization of three blood vessels approximately 1.8 to 2.5 mm in diameter, followed by contrast injection, demonstrated good embolization efficiency. Embolization of deep vessels was also successful (Figures 12A-12C). Testing showed better visibility of the gel under a fluoroscope compared to the reference sample (Figures 13A-13C).

[0097] Example 14. Addition of drugs to composite gel liquid embolic preparations and release of drugs from composite gel liquid embolic preparations A doxorubicin solution (25 mg / mL) was thoroughly mixed with an aqueous solution (20%) of the triblock copolymer by forcing it between the two syringes through a three-way stopcock. After delivery into 37°C PBS, the drug-loaded, solidified embolic hydrogel gradually began to release doxorubicin. After 24 hours, the solution was red, indicating drug release. The solution was then replaced with fresh 37°C PBS, which again turned red after 24 hours, indicating continued drug release. The following corresponds to claims 1 to 15 at the time of filing. (Appendix 1) A medical composition comprising an aqueous solution of a block copolymer comprising one or more poly(N-isopropylaminoacrylamide) blocks and one or more poly(2-(di-(C3-5)alkylamino)ethyl methacrylate) blocks, wherein each C3-5 alkyl group is independently selected from propyl, butyl, and pentyl groups, and the composition is in liquid form at 25°C. (Appendix 2) The composition according to Appendix 1, wherein the one or more poly(2-(di-(C3-5)alkylamino)ethyl methacrylate) blocks are poly(2-(dibutylamino)ethyl methacrylate) blocks. (Appendix 3) The composition according to appendix 1 or 2, wherein the composition has a pH in the range of 5 to 6. (Appendix 4) The composition of any one of Appendices 1 to 3, wherein the composition becomes a gel when injected into phosphate buffered saline having a pH of 7.4 and a temperature of 37°C. (Appendix 5) The composition according to any one of Appendices 1 to 4, wherein the block copolymer is a triblock copolymer having two poly(N-isopropylaminoacrylamide) blocks and one poly(2-(di-(C3-5)alkylamino)ethyl methacrylate) block, or the block copolymer is a triblock copolymer having one poly(N-isopropylaminoacrylamide) block and two poly(2-(di-(C3-5)alkylamino)ethyl methacrylate) blocks. (Appendix 6) The composition of any one of Appendices 1 to 5, wherein each of the one or more poly(N-isopropylaminoacrylamide) blocks in the block copolymer is in the range of 5 to 600 monomer units in length. (Appendix 7) The composition of any one of Appendices 1 to 6, wherein each of the one or more poly(2-(di-(C3-5)alkylamino)ethyl methacrylate) blocks in the block copolymer is in the range of 50 to 300 monomer units in length. (Appendix 8) The composition according to any one of Appendices 1 to 7, wherein the number average molecular weight of the block copolymer is in the range of 2,000 to 500,000 Da. (Appendix 9) The composition according to any one of Appendices 1 to 8, wherein the composition has a viscosity in the range of 10 mPa·s to 5000 mPa·s when measured at a temperature of 25°C and a shear rate of 50 1 / s. (Appendix 10) The composition of any one of Appendices 1 to 9, wherein the block copolymer further comprises an additional polymer block having a length ranging from 1 to 500 monomer units and comprising an amine group. (Appendix 11) The composition according to any one of Appendices 1 to 10, further comprising an anionic polymer containing negatively charged groups selected from sulfonate groups, sulfate groups, phosphate groups, phosphonate groups, and carboxylate groups. (Appendix 12) The composition of Appendices 11, wherein the anionic polymer is selected from sulfonate polymers, polyphosphates, poly(carboxylic acids), and negatively charged polysaccharides, preferably poly(2-acrylamido-2-methylpropanesulfonate). (Appendix 13) The composition according to any one of Appendices 1 to 12, further comprising an imaging agent or a therapeutic agent. (Appendix 14) The composition according to any one of Appendices 1 to 13, wherein the composition is provided in a vial or syringe barrel. (Appendix 15) Use of the composition according to any one of Appendices 1 to 14 as an embolic agent, fiducial marker, tissue filler, tissue spacer, or therapeutic agent depot.

Claims

1. One or more poly(N-isopropylaminoacrylamide) blocks and one or more poly(2-(di-(C ３～５ 1. A medical composition comprising an aqueous solution of a block copolymer comprising a C) alkylamino) ethyl methacrylate) block, wherein each C ３～５ A composition wherein the alkyl groups are independently selected from propyl, butyl, and pentyl groups, and which is in liquid form at 25°C.

2. the one or more poly(2-(di-(C ３～５ 2. The composition of claim 1, wherein the poly(2-(dibutylamino)ethyl methacrylate) block is a poly(2-(dibutylamino)ethyl methacrylate) block.

3. 3. The composition of claim 1, wherein the composition has a pH in the range of 5 to 6.

4. 3. The composition of claim 1 or claim 2, wherein the composition becomes a gel when injected into phosphate buffered saline having a pH of 7.4 and a temperature of 37°C.

5. The block copolymer comprises two poly(N-isopropylaminoacrylamide) blocks and one poly(2-(di-(C ３～５ a triblock copolymer having one poly(N-isopropylamino)acrylamide) block and two poly(2-(di-(C ３～５ 3. The composition of claim 1 or claim 2, wherein the copolymer is a triblock copolymer having a) alkylamino) ethyl methacrylate) block.

6. 3. The composition of claim 1 or claim 2, wherein each of the one or more poly(N-isopropylaminoacrylamide) blocks in the block copolymer ranges from 5 to 600 monomer units in length.

7. The one or more poly(2-(di-(C ３～５ 3. The composition of claim 1 or claim 2, wherein each of the ()alkylamino)ethyl methacrylate) blocks ranges from 50 to 300 monomer units in length.

8. 3. The composition of claim 1 or claim 2, wherein the number average molecular weight of the block copolymer is in the range of 2000 to 500,000 Da.

9. 3. The composition of claim 1, wherein the composition has a viscosity in the range of 10 mPa·s to 5000 mPa·s when measured at a shear rate of 50 1 / s at a temperature of 25°C.

10. 3. The composition of claim 1 or claim 2, wherein the block copolymer further comprises an additional polymer block ranging from 1 to 500 monomer units in length that comprises an amine group.

11. 3. The composition of claim 1 or claim 2, further comprising an anionic polymer containing negatively charged groups selected from sulfonate groups, sulfate groups, phosphate groups, phosphonate groups, and carboxylate groups.

12. 12. The composition of claim 11, wherein the anionic polymer is selected from sulfonate polymers, polyphosphates, poly(carboxylic acids) and negatively charged polysaccharides, preferably the anionic polymer is poly(2-acrylamido-2-methylpropanesulfonate).

13. 3. The composition of claim 1 or claim 2, further comprising an imaging or therapeutic agent.

14. 3. The composition of claim 1 or claim 2, wherein the composition is provided in a vial or syringe barrel.

15. 10. Use of the composition of claim 1 or claim 2 in the manufacture of an embolic agent, a fiducial marker, a tissue filler, a tissue spacer, or a therapeutic agent depot.

Images